Studies have illustrated that there are large pools of glial progenitor cells (GPCs) in the human neocortex [1] [2] [3] [4] [5] [6] [7] [8] [9] . There are different antigen phenotype classifications for GPCs such as: A2B5-positive cells 4, 10 and NG2-expressing cells [11] [12] [13] [14] . The predominant cell type in injured brains are NG2-positive cells 1, 15 . Although, it is still controversial whether GPCs are able to generate new neurons in their local brain regions 16, 17 , It is well-known that after environmental limits in healthy brains were depleted, the stem/progenitor cells from non-neurogenic regions could restore self-renewal and generate new neurons 2, [4] [5] [6] [7] [8] [18] [19] [20] .
Recent studies have shown that NG2 + GPCs isolated from postnatal rodents were able to form neurospheres and generate new neurons and glia [11] [12] [13] [14] .
Alzheimer's disease (AD) is a neurodegenerative diseases and is characterized by amyloid plaque deposits and neurofibrillary tangles 21, 22 . Damage-induced neurogenesis has not been demonstrated in the neocortex after progressive neuronal loss in AD brains 23, 24 , although significant gliogenesis was observed in the degenerative cortex 25 .
The mechanism that underlined the fate of GPCs remains unclear, however several signal transduction pathway cascades have been shown to control progenitor cell fate 26 . One of these pathways, Wnt/β-catenin signal cascade, was involved in progenitor cell lineage decisions 27 in developmental stages [28] [29] [30] as well as in adult brains 31 . A reduced Wnt/β-catenin signaling has been reported in AD brains 32, 33 , and the decreased expression of β-catenin was also found in AD patients carrying presenilin-1-inherited mutations [34] [35] [36] .
In the current study, we found that new neuron productions of AD GPCs were significantly reduced compared to HC brain samples. Furthermore, reduced β-catenin signaling was observed in AD neurospheres and their differentiated cells. Exogenous Aβ treating interrupted the neuron fate commitment of HC GPCs. These results suggested that reduced β-catenin signaling causes a decrease in neurogenesis of AD GPCs.
RESULTS

Generation of new neurons reduces from AD glial progenitor cells
Increased Aβ in AD brains is produced by neurons. In order to investigate whether Aβ production is also promoted in AD GPCs, both Aβ40 and Aβ42 levels in GPCs were measured with ELISA. We found an approximate one-fold increase in both Aβ40 and Aβ42 level in AD (n = 3) GPCs to their HC (n = 3) counterpart (Fig. 1a) . Furthermore, we tested the Aβ level of the daughter cells derived from the reprogrammed GPCs. These results have shown a similar increase in Aβ40 and Aβ42 in cells from AD GPCs as compared to HC cells (Fig. 1a) . Because Aβ is generated in a vesicular pathway, it has little effect on the extra-vesicular components. Therefore, we tested Aβ level in the medium, and normalized both Aβ40 and Aβ42 to the total proteins of the corresponding cell lysate. As expected, both Aβ40 and Aβ42 levels increased in the medium of AD GPCs, with a prominent increase of Aβ42 level in the medium containing AD daughter cells (Fig. 1b) .
Whether there are any potential differences in the developing fate of HC and AD GPCs, we observed the cell differentiation toward neurons with doublecortin (DCX)
labeling, a neuroblast cell marker, at 2-days in culture (Fig. 1c) . Respectively, 6% and 2% of scored HC and AD cells displayed DCX positive staining (Fig. 1d) . To further clarify the immunostaining results, we applied Western blot analysis for the progeny cells. In addition to reduced DCX level in AD progeny cells, polysialic acid-neural cell adhesion molecule (PSA-NCAM), a neuroblast marker, was reduced at 2 days in culture (Fig. 1e) . The results revealed a decline in the production of new neurons from AD GPCs.
Thus far, it is not clear whether a decline of new neurons from AD GPCs is due to changes in proneural gene expression. Therefore, we tested the expressions of the proneural genes; neurogenin 2 (Ngn2) and mammalian achaete-scute homolog 1 (Mash1), members of the helix-loop-helix class of transcription factors and neurogenic differentiation factor 1 (NeuroD1) by Western blot. It has been reported that neurogenins inhibit glial differentiation 37 , which was reflected in the results that illustrated a significantly reduced expression of Ngn2, Mash1, NeuroD1 in AD differentiated cells at 2 days in culture (Fig. 1f) . This information suggests that the decline of neurogenic gene expression might be associated with the reduction of new neurons derived from AD GPCs.
β-catenin signaling decreases in AD glial progenitor cells and their daughter cells
As studies have shown, Wnt/β-catenin signaling can trigger the differentiation of GPCs into neuron phenotype cells 27 . The over-expression of Wnt3 was significant enough to increase neurogenesis from adult human progenitor cells, however, a blockade of Wnt3 signaling reduced neurogenesis 31 . Reduced Wnt/β-catenin signaling has been reported in those with AD 32, 33 . Therefore, it was postulated that deficiency in the Wnt/β-catenin cascade could be the reason why there was a reduction in neuron production from AD GPCs. In order to examine whether Wnt/β-catenin signaling pathway is involved in a different cell fate decision between HC and AD GPCs, the signaling molecules in the GPCs and their daughter cells were tested by Western blot. We found no significant differences in Wnt3 and Wnt3 receptor frizzled expression between AD and HC GPCs as well as their progeny cells (Fig. 2a) . However, β-catenin, which is the downstream effector of Wnt3 signaling, was significantly decreased in AD GPCs and their progeny cells compared to those from HC samples (Fig. 2a) , although the cause of the decline is unclear.
As previously mentioned, GSK-3β is an enzyme which phosphorylates β-catenin [38] [39] [40] .
Adding Aβ promoted GSk-3β expression and activity in neurons 39 , which, in turn, induced β-catenin phosphorylation to degradation. In order to examine whether β-catenin reduction is also associated with GSk-3β levels in neuronal induction, we tested the expression of GSk-3β in AD and HC GPCs and their daughter cells by Western blot. We found a significant increase in GSk-3β expression in AD GPCs and their differentiated cells (Fig.   2a ). It is still unclear whether the increased GSk-3β level might promote the phosphorylation of β-catenin in AD GPCs. The phosphorylated β-catenin was detected with an antibody against phosphorylated β-catenin by Western blot. We have also found a significant increase in phosphorylated β-catenin in AD GPCs and the progeny cells ( Fig.   2a ). Due to nuclei translocation of β-catenin, so we need to demonstrate whether decreased β-catenin is also found in the nucleus. Immunohistochemistry demonstrated that the expression of β-catenin was decreased in the nuclei of AD daughter cells (Fig. 2b) .
Meanwhile, we isolated the nucleus and cytoplasm of differentiating cells and also found a similar decrease in β-catenin level in both the nucleus and cytoplasm of AD progeny cells.
We observed trace levels of GSK-3β and phosphorylated β-catenin in the nucleus extraction, however, a significant increase in the level of GSK-3β and phosphorylated β-catenin were found in the cytoplasm of AD progeny cells (Fig. 2c) .
It has also been reported that Ngn1 and Ngn2 are the proneural genes that are controlled by β-catenin 41 . Over-expression of β-catenin could significantly increase the luciferase activity in the reporter assay 41 . We found that β-catenin levels in AD GPCs and their daughter cells were significantly lower than HC cells. Therefore, it would be interesting to find out whether these pro-neuronal genes could be lowered at mRNA level.
We performed RT-PCR to examine the mRNA level of Ngn1 and Ngn2. The results
showed that both Ngn1 and Ngn2 mRNA levels were decreased in AD daughter cells, indicating a decrease in β-catenin level in the cells derived from AD GPCs causes a corresponding reduction in pro-neural gene expression, which lowers its ability to differentiate towards neurons (Fig. 2d, e) .
Amyloid-β peptide impairs neuronal induction by reducing β-catenin level
Increased Aβ production and deposits are the hallmarks of AD progression 21, 22 . To find out whether Aβ toxicity could have an inhibitory effect on the neuron-generated capability of NG2 + GPCs, HC spheres were treated with different concentrations of Aβ1-42 peptide, the primary component in the medium of AD progeny cells (Fig. 1 b) , for 2 days, then Aβ was removed and the cultures were tested at either 7 or 14 day periods. At 0.1 μM of Aβ42, no decrease in βIII tubulin + neurons was observed as compared to the sample without Aβ42 treatment (Fig. 3a, b) . A similar result was also found by MAP-2 staining (data not shown).
When treated the cells with 1 μM of Aβ42, we found βIII tubulin + new neurons were significantly decreased (* P < 0.05), however, when treated with 5 μM of Aβ42, βIII tubulin + and MAP-2 + neurons were greatly reduced (Fig. 3a , b, ** P < 0.01). Our results indicated that exogenous Aβ could inhibit GPCs capability to generate neurons in a dose-dependent manner.
To understand whether the decreased production of new neurons by Aβ42 treatment is due to the change of proneural genes, HC progeny cells were exposed to Aβ 42 for 2 days and the culture was kept for 14 days after the removal of Aβ 42. After 14
days, the cells were tested by Western blot. The results demonstrated reduced expressions of the neurogenic genes Ngn2, Mash1, and NeuroD1 in the cells with Aβ42 treatment (Fig. 3c) , suggesting that transient treatment of Aβ42 could have a long lasting effect on the neuron-fate decision.
Since treatment with Aβ42 could interrupt neuron induction, we further examined whether Aβ treatment could affect the same signal pathway we found in the cells from AD GPCs. The Western blot detected Wnt3/β-catenin signaling molecules. Similar to the results we found in the cells derived from AD GPCs, we did not observe any significant change in Wnt3 and frizzled expression between cells with and without Aβ42 treatment (Fig. 3d) . However, in Aβ42 treated HC progeny cells, we found that the expression of β-catenin was significantly decreased in a dose-dependent manner (Fig. 3d) . We also investigated the phosphorylation of β-catenin and GSK-3β expression along with Aβ treatment. As expected, the expression of phosphorylated β-catenin and GSK-3β was enhanced along with 5 µM of Aβ42 treatment in HC progeny cells (Fig. 3d) . Meanwhile, Aβ treatment also further promoted GSK-3β expression of AD cells. However, significant changes were not observed in the expression of β-catenin and phosphorylated β-catenin between AD cells with and without Aβ42 treatment (Fig. 3d) . These data indicate that Aβ up-regulates GSK-3β expression, which, in turn, reduces β-catenin levels in newly generated cells.
β-catenin transfection restores the neuronal induction of AD GPCs
To establish a causal relationship of reduced neurogenesis derived from AD GPCs, we observed whether the restoration of neuronal differentiation in AD neurospheres by promoting β-catenin in the Wnt signaling pathway. Suspended NG2 + progenitor cells from AD brains (n = 2) were transfected by the virus with β-catenin for 5 h followed by a 14-day extension of the culture. The spheres infected the virus with β-catenin were dissociated into single cells and cultured in the differentiating medium for 4 days. The controls were non-transfected β-catenin cells HC (n = 2) and AD (n = 2) and Western blot analysis has demonstrated that the expression level of β-catenin was partially restored (Fig. 4a) .
Immmunostaining with βIII tubulin has shown a significant increase in the neuron number with β-catenin introduction (Fig. 4b, c) .
DISCUSSION
Recently the statement, "neurons do not regenerate during adulthood," has been challenged, and studies have found evidence that mature brains are capable of regenerating neurons 42 . There are more studies now showing GPCs, such as isolated NG2 + progenitor cells from postnatal, as well as adult rodents, were able to form neurospheres and generate mature neurons and glial cells 12, 43 . However, newly generated neurons have not been observed in the neocortex after progressive neuron loss 23, 24 due to damage by toxic Aβ deposits 44, 45 . Although neural progenitor cells both in vivo and isolated cells were reported [46] [47] [48] [49] , how the fate of the progenitor cells was affected, especially from AD patients has yet to be investigated. In the current study, even at older ages (over 80 years old), the progenitor cells isolated from the neocortex still have the competence to renew and generate new neurons. However, in the brains of AD patients, the self-renewal ability reduced gradually with time in comparison to the rate of renewal like those from the healthy brain samples. The neurogenesis was dramatically reduced in AD and Aβ treating HC cells; in vitro experiments showed such impairment might be due to Aβ down-regulated β-catenin level therefore inhibited the neuron induction of GPCs.
It has been reported that Aβ promotes neuronal apoptosis in AD by activating GSK-3β, leading to the degradation of β-catenin and inactivation of Wnt signaling 50 .
Activation of Wnt signaling rescues neurodegeneration and behavioral impairments
induced by β-amyloid fibrils 51, 52 . Similarly, studies have shown that the activation of PKC by phorbol 12-myristate 13-acetate protected rat hippocampal neurons from Aβ toxicity.
Such effect was accomplished by the inhibition of GSK-3β activity, which led to the accumulation of cytoplasmic β-catenin and transcriptional activation via β-catenin/T-cell factor/lymphoid enhancer factor-1 (TCF/LEF-1) of Wnt target genes 53 . In contrast, inhibition of Ca 2 + -dependent PKC isoforms activated GSK-3β and offered no protection from Aβ neurotoxicity 53 .
One pathway, Wnt/β-catenin signaling pathway, has been known to promote self-renewal in a variety of tissue stem cells, including neural stem cells, and hematopoietic stem cells. However, activation of the Wnt/β-catenin pathway promoted the inhibition of the pathway and prevented the differentiation of neural precursor cells 31, 54 . We have found that Aβ can also cause permanent damage to GPCs by decreasing β-catenin level, so they can decrease the production of new neurons even though a transient toxic dose of Aβ was applied, suggesting Aβ may play a toxic role in neurons and progenitor cells in a similar manner [55] [56] [57] [58] . Amyloid beta (Aβ) toxicity on neurons could be reversed by reagents like PKC agonist or Lovastatin, a reagent that could affect cholesterol synthesis and reduce Aβ production 50, 53 , whether these reagents could be used on GPCs to restore their capability of neuron induction remains to be further studied.
In conclusion, the potential capability of GPCs and other neural precursor cells could be disrupted due to the effect of Aβ toxicity by lowering cellular signaling molecule β-catenin level. Therefore, there are still GPCs that exist inside the brain, and fail to generate new neurons to compensate for the neuron loss caused by Aβ aggregation. Also, due to the lack of necessary growth factors in AD brains, it could be possible that GPCs primarily differentiate into glial cells, which is consistent with previous studies 25 . Finally, how to lower the toxic effect of Aβ and/or elevate β-catenin level of AD GPCs by the inhibition of GSK-3β 40 or other neuron progenitor cells will be the key to restore its neuron development fate (Fig. 5 ). Neuron number was significantly promoted with β-catenin introduction.
METHODS
Figure 5:
The schematic presentation shows that Aβ elevates GSK-3β, which in turn promotes the phosphorylation and degradation of β-catenin. Reduced β-catenin signaling down-regulates the expression of proneural genes.
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